Post-GRAIL, Illumina is refocusing on NovaSeq X and clinical consumables—using multiomics and AI to defend its sequencing moat amid China and competition headwinds.
Overview
Illumina enters 2026 in a markedly improved strategic posture after divesting GRAIL (June 2024 spin-off; Illumina retained 14.5%) following adverse FTC/EC rulings. The divestiture increased debt and reduced liquidity (including a $750M term loan to help capitalize GRAIL), but removed a major regulatory overhang and eliminated the drag of GRAIL’s operating losses—allowing renewed focus on core sequencing. FY2025 was a stabilization year: revenue was flat at $4.343B, yet ex-China demand grew and accelerated late in the year; margins improved through cost actions. Q1 FY2026 provided a clearer recovery signal with revenue up 4.8% YoY, stronger operating margins, higher EPS, robust free cash flow, and raised 2026 guidance. The investment debate now centers on the durability of clinical consumables growth, the competitive response to low-cost and long-read challengers, and execution of the SomaLogic-driven multiomics/AI expansion amid persistent China/geopolitical headwinds.